Skip to main content
Prelude Therapeutics Inc logo

Prelude Therapeutics Inc — Investor Relations & Filings

Ticker · PRLD ISIN · US74065P1012 US Manufacturing
Open in API
Filings indexed 356 across all filing types
Latest filing 2022-02-16 Investor Presentation
Country US United States of America
Listing US PRLD

About Prelude Therapeutics Inc

https://preludetx.com/

Prelude Therapeutics is a clinical-stage precision oncology company focused on discovering and developing innovative medicines for cancer patients with high unmet needs. The company's pipeline features small molecule therapies and leverages expertise in targeted protein degradation. Key development programs include highly selective KAT6A degraders for solid tumors, such as ER+ breast cancer, and mutant-selective JAK2V617F JH2 inhibitors for myeloproliferative neoplasms. Prelude is also advancing next-generation degrader antibody conjugates (DACs) with novel payloads. The company's science-driven approach targets critical cancer cell pathways to create potentially transformative treatments.

Recent filings

Filing Released Lang Actions
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 16, 2022, by Prelude Therapeutics Incorporated. The key content is the disclosure of investor presentation materials attached as Exhibit 99.1, which the company intends to use for investor presentations. The document explicitly states that the presentation materials are attached and incorporated by reference, and the filing is a current report under Regulation FD Disclosure. There are no financial statements or detailed financial data included in the text, only a reference to the presentation. The document length is 3463 characters, which is relatively short and consistent with an announcement-type filing rather than a full report. According to the classification rules, when a document primarily announces or attaches an investor presentation, it should be classified as Investor Presentation (IP).
2022-02-16 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-02-09 English
SC 13G/A
Major Shareholding Notification
2022-02-04 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated January 10, 2022. It includes a Regulation FD Disclosure about investor presentation materials prepared by the company, which are attached as Exhibit 99.1. The text explicitly states that the materials are investor presentation materials to be used by management for presentations. There is no substantive financial data or detailed report content within the text itself, only a reference to the presentation. The document length is 3462 characters, which is relatively short and consistent with an announcement or filing referencing an attached presentation. According to the classification rules, this type of document is best classified as an Investor Presentation (IP).
2022-01-10 English
FORM 4 SUBMISSION
Director's Dealing
2022-01-05 English
FORM 4 SUBMISSION
Director's Dealing
2021-12-17 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.